Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if therapeutic dose anticoagulation (experimental
group) improves 30-day mortality in participants with COVID-19 compared to those patients
receiving the intermediate dose prophylaxis (control group). Following screening, subjects
will be randomized 1:1 to intermediate dose prophylaxis or therapeutic dose anticoagulation
treatment arms.Treatment will continue for 28 days, followed by a 6 month follow-up period.